DRUG.US Bright Minds Biosciences Inc

Healthcare Biotechnology USA Stocks
23.11 USD
Close of Nov 14, 2026
17.40 123.75
Market cap
USD 228M
P/E
-
P/B
1.03x
ROE
-8.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is DRUG.US undervalued?

Graham number

The Graham number of Bright Minds Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bright Minds Biosciences Inc fundamental analysis

No fundamental analysis for Bright Minds Biosciences Inc yet.

Bright Minds Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bright Minds Biosciences Inc

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. Th…

Full company profile